A Wharton–Penn team is testing whether GLP-1 drugs can cool the brain’s urge to gamble and splurge.
Story Snapshot
- Penn researchers launched a first-of-its-kind study on GLP-1 drugs and risky money choices.
- The study measures gambling and impulse buying behavior alongside brain responses.
- Early reports say users feel less pull to gamble or shop, which motivates the trial.
- The lead scientist says changes in brain reward circuits may shape financial choices.
Penn study targets the link between GLP-1 and money decisions
Researchers at the Wharton School and the University of Pennsylvania began a study to see if GLP-1 drugs affect risky financial behavior, such as casino betting and impulsive shopping. The plan calls for about 180 adults to complete money-choice tasks and brain scans while exposed to cues like jackpot images. Testing runs at Penn’s MindCORE lab from mid-October 2026 to roughly March 2027, according to reporting on the protocol and timeline.
The trial measures whether people on GLP-1 show less drive for fast rewards. Tasks probe choices like smaller-sooner cash versus larger-later cash. Imaging tracks reward-circuit activity when seeing gambling or luxury prompts. The goal is direct evidence on whether the drugs change how the brain values risk, reward, and waiting. Public coverage describes questionnaires, cognitive tasks, and repeated scans, though it does not detail randomization or control arms.
Why the reward hypothesis took center stage
GLP-1 drugs help control appetite, but scientists have long mapped GLP-1 receptors inside brain regions that handle reward and motivation. That biology suggests the drugs could dampen multiple reward-driven urges, not just food cravings. Observational reports from users describe less interest in drinking, smoking, gambling, and excessive shopping. Those firsthand accounts do not prove cause, but they explain why labs now test money choices and cue responses under GLP-1 exposure.
Michael Platt, a neuroscientist at Wharton, has linked the science to dollars and cents. He argues that GLP-1 exposure may remodel brain circuits tied to reward over time, which could shift both food choices and financial decisions. He has said the team expects changes that reach beyond appetite into how people weigh risky bets or flashy purchases. That claim sets a clear, testable path for this study’s scans and behavior tasks.
How the study could change real-world habits
The key prediction is simple and powerful: less chasing of quick thrills. If GLP-1 dulls the pull of immediate rewards, people should show fewer impulsive clicks on shopping carts and fewer heat-of-the-moment wagers. That should show up in lab tasks first, then, ideally, in spending and betting logs. The Penn effort plans to analyze valuation of money and reward signals while people view casino-style images and other triggers tied to financial risk.
Framing compulsive shopping as a GLP-1 problem worries me. Those drugs blunt reward signals broadly, so less spending may just mean less wanting anything, not better self-control. Where do you draw the line between treating addiction and dulling normal desire?
— Sophie ⭐ ⭐ (@ootani_fx_c) October 9, 2026
The wider addiction field gives this approach a foundation. Prior research points to GLP-1 actions in reward circuits and reports reduced seeking for alcohol and drugs in animal models and early human work. That history does not equal proof for gambling or shopping. But it offers a clear rationale to ask whether the same neural levers can nudge money behavior in safer directions, especially when mixed with skills-based therapy and guardrails like spending limits.
What to watch next: signals that matter
Three results would mark real progress. First, a measurable drop in impulsive money choices while on GLP-1, even when temptations are vivid. Second, a matching drop in reward-circuit response to gambling or luxury cues on brain scans. Third, some carryover to real accounts: fewer sportsbook deposits, fewer late-night orders, and smaller high-risk losses. Public reporting so far describes plans and motives but no clinical outcomes, which the team will need to deliver over time.
One brief caveat applies: media reports describe an ongoing plan, not completed randomized results, so durability and clinical impact remain to be shown. Still, the setup is strong. The study names its targets, builds on known brain biology, and defines behaviors that can be counted. If those measures move in lockstep, expect fresh debates on using GLP-1 alongside therapy to tame gambling and shopping binges, with strict attention to cost, safety, and personal responsibility.
Sources:
cbsnews.com, oglobo.globo.com, health.harvard.edu
